DNAtrix to Present Results of DNX-2401 for Recurrent Glioblastoma at ASCO 2017

Friday, June 2, 2017 Genetics & Stem Cells News
Email Print This Page Comment bookmark
Font : A-A+

HOUSTON, June 1, 2017 /PRNewswire/ -- DNAtrix, a biopharmaceutical company developing oncolytic virus immunotherapies for

cancer, announced today that it will present favorable safety and efficacy data for its lead adenovirus-based product, DNX-2401 (tasadenoturev), for the treatment of glioblastoma at the 2017 Annual Meeting of the American Society of Clinical Oncology
(ASCO) in Chicago, IL.

The clinical trial results will be presented by investigator Frederick F. Lang, MD, FACS, FAANS, Director of Clinical Research in the Department of Neurosurgery at The University of Texas MD Anderson Cancer Center.  The study showed that DNX-2401 administered intratumorally provided clinical benefit and extended survival for patients with recurrent glioblastoma.

"We are honored that our study for recurrent glioblastoma was selected for an oral presentation at ASCO," said Frank Tufaro, PhD, CEO of DNAtrix.  "There are very few treatment options at this stage of disease, and we are excited about the possibility that a single dose of DNX-2401 could provide benefit and has the potential to improve the lives of patients and their families."

Details of the presentation are as follows:

Title: Phase 1b Open-Label Randomized Study of the Oncolytic Adenovirus DNX-2401 Administered with or without Interferon Gamma for Recurrent GlioblastomaSession: Central Nervous System TumorsPresenter: Frederick F. Lang, MD, FACS, FAANSDate: Sunday, June 4, 2017, 8:24 - 8:36 AM CDTLocation: S100a

For more information about DNAtrix clinical studies, visit the website ClinicalTrials.gov: NCT02197169 (DNX-2401 ą interferon gamma) and NCT02798406 (DNX-2401 + KEYTRUDA).

About DNX-2401

DNX-2401 is an investigational oncolytic immunotherapy designed to treat cancer. DNX-2401 sets off a chain reaction of tumor cell killing by selectively replicating within glioblastoma cells (but not normal cells), causing tumor destruction and further spread of the oncolytic virus to adjacent tumor cells. This process then triggers an immune response directed against the tumor. DNX-2401 has been well tolerated in patients with recurrent glioblastoma and survival has been prolonged compared to other therapies.

About DNAtrix

DNAtrix is a privately held, clinical stage, biopharmaceutical company developing oncolytic virus immunotherapies for cancer. DNAtrix's lead product, DNX-2401, is a conditionally replicative oncolytic adenovirus being evaluated in clinical trials for recurrent glioblastoma, a brain cancer for which there is neither a cure nor adequate treatment. The company is backed by Morningside Ventures and Mercury Fund, and has been awarded a grant from the Cancer Prevention and Research Institute of Texas (CPRIT).  For more information, please visit the company website at www.dnatrix.com.

ContactDNAtrixImran Alibhai, Ph.D.S.V.P. Business Developmentialibhai@dnatrix.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/dnatrix-to-present-results-of-dnx-2401-for-recurrent-glioblastoma-at-asco-2017-300467483.html

SOURCE DNAtrix



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook